Evonik's China Strategy Gains Altitude with Medical and Mobility Breakthroughs

Evonik gains landmark NMPA approval for 3D-printed cranial implants and supplies polymers for China's drone/eVTOL market, driving strategic growth.

German specialty chemicals group Evonik is making significant inroads into China's high-growth sectors, securing a landmark medical approval while positioning itself as a key supplier for the country's emerging low-altitude economy. This dual-track strategy in specialized niches is unfolding as the company's shares show considerable strength, having climbed nearly 30% since the start of the year to trade at EUR 17.31.

A major regulatory milestone has been achieved in the healthcare sector. Evonik has received the first Chinese registration certificate for patient-specific cranial implants manufactured from its specialized 3D printing filaments. The National Medical Products Administration (NMPA) also granted approval for spinal implants based on the company's polymers, marking a historic entry into the tightly regulated Chinese medical market.

Simultaneously, the company is targeting China's ambitious "Low-Altitude Economy" initiative. At the upcoming CHINAPLAS trade fair in Shanghai, starting April 21, Evonik will showcase high-performance polymers designed for drones and electric vertical take-off and landing aircraft (eVTOLs). These lightweight materials are critical for improving the range and energy efficiency of next-generation urban air mobility vehicles.

Beyond aerospace and medicine, Evonik is launching industrial and consumer-focused innovations. The company introduced "Easy Slide 2," a novel material for plain bearings that withstands extreme temperatures and pressures. Its key competitive advantage is the complete absence of fluoropolymers like PTFE, offering a strategic, future-proof alternative for industries concerned about potential bans on PFAS, or "forever chemicals."

Complementing this, Evonik's beauty care division will unveil a new branding and a focus on bio-based, biodegradable ingredients at the in-cosmetics Global event in Paris in mid-April.

This broad-based innovation push is underpinned by solid financials. For the full year 2025, Evonik reported an adjusted EBITDA of EUR 1.9 billion. Management has reaffirmed its full-year guidance, which projects an adjusted EBITDA between EUR 1.7 and 2.0 billion on sales of EUR 13.5 to 14.5 billion.

The company's capital allocation policy is also evolving. While a stable dividend of EUR 1.00 per share is proposed for 2025, a new flexible payout ratio will take effect from 2026. The board plans to distribute 40% to 60% of adjusted net income, a move designed to protect the balance sheet during cyclical downturns.

Analysts are actively assessing the stock. Goldman Sachs holds a price target of EUR 20, highlighting cost advantages in the methionine business. Deutsche Bank recently upgraded its rating to "Hold" with a EUR 15 target.

Investors await the next key data point with the release of first-quarter 2026 figures on May 8. Although observers anticipate a slight year-on-year decline in earnings, the company's strategic progress in high-margin specialties is drawing increased market attention. The stock's 14-day Relative Strength Index (RSI) of 38.9 suggests it is not in overbought territory following its recent advance. The Annual General Meeting is scheduled for June 3, 2026.